Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation
Ahsun Riaz(Northwestern University), Riad Salem(Northwestern University), Vanessa L. Gates(Society of Interventional Radiology), Al B. Benson(Northwestern University), Khairuddin Memon(Northwestern University), Robert J. Lewandowski(Society of Interventional Radiology), Mary F. Mulcahy(Northwestern University), Ritu Nayar(Northwestern University), Paul Nikolaidis(Northwestern University), Reed A. Omary(Vanderbilt University), Robert K. Ryu(University of Colorado Anschutz Medical Campus), Michaël Abécassis(University of Arizona), Ramona Gupta(Northwestern Memorial Hospital), Frank H. Miller(Northwestern University), Laura Kulik(Northwestern University), Ed Wang(Northwestern University), Kent T. Sato(Society of Interventional Radiology), Talia Baker(University of Utah)
Cited by 147
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k